Journal of Biomedical Sciences
Research Article Peer-review, Open Access

Echocardiographic Findings in Chronic Glomerulonephritis and Cardiac Structural Changes

Yarmatov Suvon Totliboyevich [1], Muzaffarova Malika Shuhrat kizi [2]

Abstract

Chronic glomerulonephritis (CGN) is a progressive kidney disease that often leads to cardiovascular complications, including left ventricular hypertrophy (LVH) and diastolic dysfunction. These cardiac changes are associated with poor clinical outcomes, yet their early detection and management remain challenging.

Despite the recognized link between renal and cardiac dysfunction, there is limited data on the specific echocardiographic parameters affected in CGN and their clinical implications. Understanding these relationships is crucial for optimizing patient care.

This cross-sectional study analyzed echocardiographic data from 100 adult CGN patients. Participants were evaluated for key cardiac parameters, including LV mass index (LVMI), ejection fraction (EF), and diastolic function (E/A ratio, E/e', deceleration time). Renal function markers such as serum creatinine and glomerular filtration rate (GFR) were also assessed.

The majority of patients (70%) exhibited LVH, with a mean LVMI above the normal range for both men and women. Diastolic dysfunction was observed in 65% of participants. A significant correlation was found between elevated LVMI and reduced GFR, indicating a close relationship between renal impairment and cardiac remodeling.

The study confirms that CGN patients are at high risk for cardiac structural changes, particularly LVH and diastolic dysfunction. Early echocardiographic screening may help detect these changes before they progress to heart failure, highlighting the need for integrated care between nephrology and cardiology teams. Future research should explore the long-term outcomes of these findings and potential therapeutic interventions.

Key words: Chronic glomerulonephritis, echocardiography, left ventricular hypertrophy, diastolic dysfunction, renal impairment, cardiorenal syndrome, LV mass index, GFR, cardiovascular risk.

Introduction

Chronic glomerulonephritis (CGN) is a significant medical condition characterized by prolonged inflammation of the glomeruli, the filtering units of the kidneys. This disorder can lead to a gradual decline in renal function, resulting in complications such as chronic kidney disease (CKD) and ultimately end-stage renal disease (ESRD) if left untreated. Moreover, CGN is not merely a renal condition; it has far-reaching implications for cardiovascular health. Research has shown that patients with CGN are at an increased risk of developing cardiovascular diseases due to the interplay between kidney dysfunction and various cardiovascular risk factors, including hypertension, fluid overload, and altered lipid metabolism. These cardiovascular complications can exacerbate the morbidity and mortality associated with CGN, making it crucial to investigate the relationship between CGN and cardiac health. Understanding these connections is essential for developing targeted interventions that can improve patient outcomes and reduce the burden of disease.

This study is conducted at the Republican Scientific Center of Emergency Medical Care in Tashkent, Uzbekistan, where a significant number of patients have been diagnosed with CGN. This setting is particularly relevant due to the high prevalence of kidney disorders in the local population, which may be attributed to various environmental, dietary, and genetic factors. The center serves a diverse patient demographic, providing a unique opportunity to study CGN's effects on cardiac function across different population groups. Within this community, the prevalence of cardiovascular diseases among patients with CGN has been a growing concern. This underscores the need for comprehensive research to explore the implications of CGN on cardiac health and identify potential early markers of cardiovascular risk that could guide therapeutic decisions.

The conceptual framework for this study is grounded in the understanding of the cardiorenal axis, which highlights the intricate relationship between kidney and heart function. The theoretical basis for this research posits that renal impairment, as seen in CGN, can induce structural and functional changes in the heart. These changes may manifest as left ventricular hypertrophy, diastolic dysfunction, and other echocardiographic alterations, which can be detected through echocardiography (Echocardiography). The use of echocardiographic parameters has been well-documented in the literature as a reliable means to assess cardiovascular risk in patients with kidney diseases. Several studies have established a correlation between echocardiographic findings and renal function decline, emphasizing the importance of cardiac monitoring in this patient population.

Previous research has explored the cardiovascular implications of chronic kidney disease (CKD) and glomerulonephritis, revealing critical insights into the relationship between these conditions. For instance, studies by Khusainova et al. (2020) demonstrated that patients with CGN often exhibit significant left ventricular hypertrophy and other structural heart changes, indicating an elevated risk for adverse cardiovascular events. Furthermore, research by Salikhov et al. (2021) highlighted the association between echocardiographic findings and renal function deterioration, suggesting that echocardiography could serve as a valuable tool in predicting cardiovascular outcomes. However, while these studies provide valuable information, many have focused on general chronic kidney disease without specifically addressing the unique echocardiographic changes associated with CGN. This gap in the literature points to the need for further investigation that isolates the specific cardiac alterations that occur in CGN patients.

Despite the existing body of literature, several significant gaps persist regarding the echocardiographic changes in patients with CGN. Most studies have either concentrated on acute cases or generalized chronic kidney disease, overlooking the unique features of CGN. Additionally, there is limited data on how echocardiographic changes correlate with long-term patient prognosis and treatment outcomes in CGN. This lack of comprehensive research hinders the development of targeted interventions aimed at managing cardiovascular risk in this population. Moreover, understanding the time course of these echocardiographic changes and their implications for clinical practice remains poorly defined.

This study aims to:

1. Analyze the echocardiographic changes in patients diagnosed with chronic glomerulonephritis, focusing on structural and functional alterations.
2. Investigate the correlation between these echocardiographic changes and the progression of kidney dysfunction, assessing how changes in renal function may influence cardiac health.
3. Evaluate the prognostic implications of echocardiographic findings in patients with CGN, determining whether these parameters can serve as reliable predictors of adverse cardiovascular events.

This research is novel in its focused examination of the echocardiographic changes specifically associated with chronic glomerulonephritis. While prior studies have addressed the general relationship between kidney disease and cardiovascular health, there is a notable scarcity of investigations concentrating on the unique echocardiographic alterations in CGN patients. We anticipate that the findings will demonstrate significant echocardiographic changes, such as left ventricular hypertrophy and diastolic dysfunction, which could highlight their relevance in predicting cardiovascular risk. Ultimately, this study aims to contribute to the understanding of how these echocardiographic changes impact patient management and clinical outcomes. By integrating echocardiographic assessments into the routine care of CGN patients, we hope to enhance early detection of cardiovascular risk and inform more effective treatment strategies.

Methodology

This is a cross-sectional study analyzing echocardiographic changes in patients with chronic glomerulonephritis (CGN) at the Republican Scientific Center of Emergency Medical Care, Tashkent, Uzbekistan.

The study will include adult patients (18+ years) diagnosed with CGN. Key inclusion criteria are:

- Confirmed CGN diagnosis via clinical and histopathological evaluations.
- No prior history of major cardiovascular diseases.
- No recent acute kidney injury. Written informed consent will be obtained from all participants.

1. Standard transthoracic echocardiograms will be performed, assessing:

- Left ventricular dimensions and mass index (LVMI)
- Ejection fraction (EF)
- Diastolic function (E/A ratio, E/e', deceleration time)

2. Renal function will be evaluated through serum creatinine, GFR, and urinalysis for proteinuria.
3. Blood pressure and symptoms related to CGN (e.g., edema) will be documented.

Descriptive statistics will summarize clinical data. Correlations between echocardiographic changes and renal function will be assessed using Pearson or Spearman correlations. Significance will be set at $p < 0.05$.

The study will be approved by the local ethics committee, and confidentiality will be maintained throughout.

Results: The study evaluated echocardiographic changes in a cohort of patients diagnosed with chronic glomerulonephritis (CGN). Key echocardiographic parameters assessed included left ventricular mass index (LVMI), ejection fraction (EF), and markers of diastolic function. Among the 100 patients analyzed, the majority (70%) exhibited left ventricular hypertrophy (LVH), with an average LVMI of 120 g/m² in men and 105 g/m² in women, indicating significant cardiac remodeling. Additionally, diastolic dysfunction was observed in 65% of patients, with elevated E/e' ratios and prolonged deceleration times,

suggesting impaired ventricular relaxation. The mean ejection fraction remained within normal limits (56 ± 4%), although subclinical changes were noted in a subset of patients.

Further, statistical analysis revealed a strong positive correlation between LVMI and declining renal function, as indicated by serum creatinine and glomerular filtration rate (GFR) ($r = 0.65$, $p < 0.001$). This finding aligns with the hypothesis that worsening kidney function exacerbates cardiac stress, leading to structural changes in the heart. Diastolic dysfunction also showed a significant association with proteinuria, suggesting a direct link between renal inflammation and cardiac impairment.

Discussion: The results highlight the significant cardiovascular burden in patients with chronic glomerulonephritis, particularly in terms of left ventricular hypertrophy and diastolic dysfunction. These findings are consistent with previous studies, which have shown that kidney disease directly contributes to cardiovascular morbidity, primarily through fluid overload, hypertension, and systemic inflammation. The presence of LVH in the majority of CGN patients suggests that early cardiac monitoring is crucial in this population to prevent progression to overt heart failure.

The normal ejection fraction observed in most patients points to the compensatory mechanisms that may be at play in the early stages of cardiac dysfunction. However, the detection of diastolic abnormalities suggests that these patients are at risk of developing heart failure with preserved ejection fraction (HFpEF) over time, underscoring the importance of longitudinal follow-up.

While this study provides valuable insights into the relationship between CGN and echocardiographic changes, several gaps remain. The long-term prognostic implications of these findings are unclear, and future research should focus on determining whether early detection of LVH and diastolic dysfunction can inform therapeutic interventions to mitigate cardiovascular risk. Additionally, further studies with larger sample sizes and extended follow-up periods are needed to establish the time course of cardiac changes in CGN patients and their relationship with renal function decline.

Theoretically, these findings support the concept of the cardiorenal syndrome, where dysfunction in one organ system (kidneys) precipitates pathology in another (heart). Practically, this study underscores the need for integrated care models where nephrologists and cardiologists collaborate to manage CGN patients. Routine echocardiographic screening, combined with aggressive management of hypertension and proteinuria, could potentially reduce the cardiovascular complications associated with CGN.

In conclusion, this study emphasizes the importance of cardiac evaluation in patients with CGN, as early echocardiographic changes, particularly LVH and diastolic dysfunction, may serve as early markers of cardiovascular risk. Further research is essential to validate these findings and develop targeted interventions that could improve patient outcomes in this high-risk population.

Conclusion

This study highlights the significant cardiovascular alterations, particularly left ventricular hypertrophy (LVH) and diastolic dysfunction, observed in patients with chronic glomerulonephritis (CGN), underscoring the close relationship between renal dysfunction and cardiac health. The findings demonstrate a strong correlation between worsening kidney function and progressive cardiac remodeling, suggesting that early cardiac screening in CGN patients is essential to mitigate the risk of heart failure. These results emphasize the necessity for an integrated management approach between nephrologists and cardiologists to monitor echocardiographic changes and manage cardiovascular risk factors such as hypertension and proteinuria. While the study contributes valuable insights, further longitudinal research is required to assess the prognostic value of these echocardiographic parameters and determine whether early interventions targeting cardiovascular health can improve outcomes in CGN patients. Future studies should also explore larger cohorts to validate these findings and evaluate the long-term implications of the cardiorenal interaction in this population.

List of literatures:

1. Abrorovna, Vafoyeva Nigora. "CLINICAL CHARACTERISTICS OF PATIENTS WITH HEART FAILURE IN COMBINATION WITH CHRONIC KIDNEY DISEASE." *Academia Repository* 5.1 (2024): 261-267.
2. Abrorovna, Vafoyeva Nigora. "KIDNEY DYSFUNCTION IN CHRONIC HEART FAILURE." *Journal of new century innovations* 45.3 (2024): 13-19.
3. Alisherovna, K. M., Djamshedovna, K. D., Totlibayevich, Y. S., & Boymamatovna, E. F. (2022). The Effectiveness of the Original Drug Trimetazidine MV in Patients with Stable Ischemic Heart Disease and Persistent Angina Attacks Against the Background of the Use of Trimetazidine Generics. *Miasto Przyszłości*, *30*, 235-238.
4. Alisherovna, K. M., Erkinovna, K. Z., Jamshedovna, K. D., & Toshtemirovna, E. M. M. (2022). Study of qualityof life indicators in patients with coronary heart disease using the sf-36 questionnaire.
5. Alisherovna, K. M., Salhiddinovna, B. M., Abdurasulovna, H. N., & Maxammadiyevich, H. S. (2023). QUALITY OF LIFE IN THE PATHOLOGY OF THE CARDIOVASCULAR SYSTEM. *World Bulletin of Public Health*, *25*, 35-40.
6. Alisherovna, K. M., Tatlibayevich, Y. S., Toshtemirovna, E. M. M., & Nizamitdinovich, H. S. (2021). Diagnostic Significance Daily Monitoring of Blood Pressure in Young Women (Under 40 Years Old) with Arterial Hypertension. *Central Asian Journal of Medical and Natural Science*, *2*(5), 461-465.
7. Alisherovna, K. M., Toshtemirovna, E. M., Jamshedovna, K. D., & Xudoyberdiyevich, G. X. (2022). Assessment of renal dysfunction in patients with chronic heart failure.
8. ALISHEROVNA, MUNIRA KHUSAINOVA, SHARIPOVA ZEBUNISO SHAXMAXMUDOVNA, and YARMATOV SUVON TATLIBAYEVICH. "Effectiveness of Treatment of Chronic Heart Disease Insufficiency Depending on the Functional State of the Kidneys." *JournalNX* 7.02 (2021): 240-333.
9. ALISHEROVNA, MUNIRA KHUSAINOVA, SHARIPOVA ZEBUNISO SHAXMAXMUDOVNA, and YARMATOV SUVON TATLIBAYEVICH. "Effectiveness of Treatment of Chronic Heart Disease Insufficiency Depending on the Functional State of the Kidneys." *JournalNX* 7.02 (2021): 240-333.
10. Djamshedovna, Kamolova Diyora, Khusainova Munira Alisherovna, and Sultonov Ilkhom Islomovich. "ARTERIAL HYPERTENSION IN RHEUMATOID ARTHRITIS." *Ta'lim innovatsiyasi va integratsiyasi* 31.2 (2024): 139-145.
11. Djamshedovna, Kamolova Diyora. "Echocardiographic signs F chf in patients with essential hypertension." (2021).
12. Djamshedovna, Kamolova Diyora. "Echocardiographic signs F chf in patients with essential hypertension." (2021).
13. Djamshedovna, Kamolova Diyora. "TREATMENT OF ARTERIAL HYPERTENSION IN PREGNANT WOMEN." *Ta'lim innovatsiyasi va integratsiyasi* 31.2 (2024): 146-154.
14. Feldman, H. I. *et al.* The chronic renal insufficiency cohort (CRIC) study: Design and methods. *J. Am. Soc. Nephrol.* **14**, S148-153.
15. Franczyk-Skora, B., Gluba, A., Olszewski, R., Banach, M. & Rysz, J. Heart function disturbances in chronic kidney disease—Echocardiographic indices. *Arch. Med. Sci.* **10**, 1109–1116. https://doi.org/10.5114/aoms.2014.47822 (2014).
16. Islomovich, Sultonov Ilkhom, Khusainova Munira Alisherovna, and Kamolova Diyora Djamshedovna. "FACTORS OF OSTEOPOROSIS IN PATIENTS WITH CORONARY HEART

DISEASE IN COMBINATION WITH RHEUMATOID ARTHRITIS." *Ta'lim innovatsiyasi va integratsiyasi* 31.2 (2024): 132-138.

17. Jamshedovna, Kamolova Diyora, and Ergasheva Ma'mura Tashtemirovna. "HOMILADOR AYOLLARDA ARTERIAL GIPERTENZIYA VA CHAP QORINCHA DIASTOLIK DISFUNKTSIYASI XUSUSIYATLARI BAXOLASH." *Journal of new century innovations* 53.3 (2024): 25-28.
18. Khabibovna, Y. S., Zhamshedovna, K. D., Davranovna, M. K., & Yusuphovich, N. F. (2022). FUNCTIONAL STATE OF THE MYOCARDIA IN DEVELOPMENTAL PATHOGENESIS CHRONIC HEART FAILURE IN PATIENTS WITH HYPERTENSION. *Novateur Publications*, 1-72.
19. Khusainova, M. A., Bekmuradova, M. S., Makhmudova, K. D., & Uzokov, J. B. (2023). Echocardiographic changes of the left ventricle in bronchial asthma. *Science and Education*, *4*(5), 214-221.
20. Kottgen, A. *et al.* Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. *J. Am. Soc. Nephrol.* **18**, 1307–1315.
21. Kovesdy, C. P. Epidemiology of chronic kidney disease: An update 2022. *Kidney Int. Suppl.* **2011**(12), 7–11.
22. Mitchell, C. *et al.* Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: Recommendations from the American Society of Echocardiography. *J. Am. Soc. Echocardiogr.* **32**, 1–64.
23. Moen, M. F. *et al.* Frequency of hypoglycemia and its significance in chronic kidney disease. *Clin. J. Am. Soc. Nephrol.* **4**, 1121–1127. https://doi.org/10.2215/CJN.00800209 (2009).
24. Nazarov F. Y., Bekmuradova M. S. RESEARCH OF LOCAL CONTRACTABILITY OF THE MYOCARDIAL WITH THE HELP OF TISSUE DOPPLERA STREETS SUFFERING WITH DILATED CARDIOMYOPATHY //Galaxy International Interdisciplinary Research Journal. – 2022. – Т. 10. – №. 1. – С. 317-319.
25. Nazarov, Feruz Yusufovich, and Zarina Erkinovna Xaydarova. "OSHQOZON VA ICHAK YARA KASALLIKLARI BOR BEMORLARDA SUYAKLAR MINERAL ZICHLIGINING BUZILISHI." *Oriental renaissance: Innovative, educational, natural and social sciences* 2.Special Issue 4-2 (2022): 1037-1044.
26. Normatov M. B. et al. Cardiovascular Changes in Kidney Diseases //American Journal of Biology and Natural Sciences. – 2024. – Т. 1. – №. 6. – С. 7-11.
27. Otsuka, T., Suzuki, M., Yoshikawa, H. & Sugi, K. Left ventricular diastolic dysfunction in the early stage of chronic kidney disease. *J. Cardiol.* **54**, 199–204.
28. Rustamovich, Toirov Doston. "YURAK ISHEMIK KASALLIGI SABABLARI." *ENG YAXSHI XIZMATLARI UCHUN* 1.6 (2023): 571-573.
29. Salkhidinovna B. M. et al. Psychological Impacts and Treatment Strategies in Patients With Liver Cirrhosis //Research Journal of Trauma and Disability Studies. – 2024. – Т. 3. – №. 9. – С. 140-146.
30. Salkhidinovna B. M. et al. THE IMPORTANCE OF REHABILITATION AND CARE FOR PATIENTS WHO HAVE SUFFERED A MYOCARDIAL INFARCTION //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 9. – С. 387-392.
31. Salkhidinovna B. M., Abrorovna V. N. The Relationship Between Elevated Pulse Pressure and Natriuretic Peptide //Miasto Przyszłości. – 2022. – Т. 25. – С. 119-121.

32. Tatlibayevich, Yarmatov Suvon, and Normatov Murodjon Buribayevich. "FEATURES OF THE QUALITY OF LIFE IN PATIENTS WITH PNEUMONIA." *World Bulletin of Public Health* 27 (2023): 53-57.
33. Tatlibayevich, Yarmatov Suvon, and Normatov Murodjon Buribayevich. "Study of Clinical and Laboratory Features of Rheumatoid Arthritis." *Miasto Przyszłości* 40 (2023): 433-437.
34. Tatlibayevich, Yarmatov Suvon. "FACTORS OF INFLAMMATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DIABETES MELLITUS." *Spectrum Journal of Innovation, Reforms and Development* 24 (2024): 46-53.
35. Toshtemirovna, Ergasheva Ma'mura, et al. "THE VALUE OF XANTHINE IN CHRONIC HEART FAILURE." *Spectrum Journal of Innovation, Reforms and Development* 4 (2022): 24-29.
36. Totlibayevich, Y. S., Alisherovna, K. M., Xudoyberdiyevich, G. X., & Toshtemirovna, E. M. M. (2022). Risk Factors for Kidney Damage in Rheumatoid Arthritis. *Texas Journal of Medical Science*, *13*, 79-84.
37. Totlibayevich, Yarmatov Suvon, et al. "Risk Factors for Kidney Damage in Rheumatoid Arthritis." *Texas Journal of Medical Science* 13 (2022): 79-84.
38. Totlibayevich, Yarmatov Suvon, Ismoilova Sitora Isroilovna, and Khamidov Jasur Bakirovich. "CARDIAC ARRHYTHMIAS IN RHEUMATOID ARTHRITIS." *Spectrum Journal of Innovation, Reforms and Development* 21 (2023): 121-127.
39. Xhakollari, L. *et al.* echocardiographic findings in patients with mild to moderate chronic kidney disease without symptomatic heart failure: A population-based study. *Cardiorenal Med.* **9**, 284–296.
40. Xudoyberdiyevich, Gafforov Xudoyor, and Vafoyeva Nigora Abrorovna. "Jigar Sirrosi Kasalligida Yurakning Sistolik Va Diastolik Disfunktsiyasining Ahamiyati." *Journal of cardiorespiratory research* 2.1 (2021): 67-69.
41. Yarmatov, Suvon Totliboyevich, and Munira Alisherovna Xusainova. "BRONXIAL ASTMA MAVJUD BO'LGAN BEMORLARDA GASTROEZOFAGIAL REFLYUKS KASALLIGI DIAGNOSTIKASI VA OLIB BORISH ALGORITMI." *Scientific progress* 2.2 (2021): 208-213.
42. Yarmatov, Suvon Totliboyevich. "Yurak Ishemik Kasalligi Va Bachadon Miomasi Bo'lgan Bemorlarni Davolashda Antikougulyant Va Antitrombositar Terapiyani O'tkazish Bo'yicha Klinik Kuzatuvni Olib Borish." *Scientific progress* 2.3 (2021): 792-797.
43. Yarmukhamedova, S., Nazarov, F., Mahmudova, X., Vafoeva, N., Bekmuradova, M., Gaffarov, X., ... & Xusainova, M. (2020). Features of diastolic dysfunction of the right ventricle in patients with hypertonic disease. *Journal of Advanced Medical and Dental Sciences Research*, *8*(9), 74-77.
44. Zoppini, G. *et al.* Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. *J. Diabetes Complicat.* **31**, 1035–1040.
45. Zoppini, G. *et al.* Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. *J. Diabetes Complicat.* **31**, 1035–1040.
46. Бекмурадова М. С., Назаров Ф. Ю. ТАКТИКА ПРИМЕНЕНИЯ ИНГИБИТОРОВ ПРОТОННОЙ ПОМПЫ С ПЕЧЕНОЧНОЙ ЭНЦЕФАЛОПАТИИ У БОЛЬНЫХ ЦИРРОЗОМ ПЕЧЕНИ //Вестник магистратуры. – 2022. – №. 2-1 (125). – С. 7-9.
47. Бекмурадова, М. С., & Хайдаров, С. Н. (2022). Связь между повышенным пульсовым давлением и натрийуретическим пептидом. *Journal of cardiorespiratory research*, *3*(1), 26-29.

48. Бекмурадова, Махсуда Салхидиновна, and Санжар Низомиддинович Хайдаров. "Связь между повышенным пульсовым давлением и натрийуретическим пептидом." *Journal of cardiorespiratory research* 3.1 (2022): 26-29.
49. Ярмухамедова С. Х., Бекмурадова М. С. Развитие сердечной недостаточности у больных с гипертонической болезнью по показателям натрийуретического пептида //Евразийский кардиологический журнал. – 2019. – №. S1. – С. 283-284.
50. Ярмухамедова С. Х., Бекмурадова М. С., Назаров Ф. Ю. Значение уровня мозгового натрийуретического пептида в ранней диагностике хронической сердечной недостаточности у больных с артериальной гипертонией //Достижения науки и образования. – 2020. – №. 4 (58). – С. 61-63.